Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.
Most Ditch GLP-1 Drugs for Weight Loss Within a Year
Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
The dark side of weight loss drugs no one warns about
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these popular medications.
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is hunting for new patients to maintain its crown as Europe’s most valuable company.
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
Axios Charlotte on MSN3d
Demand for GLP-1s for weight loss is surging in North Carolina, just like it is nationwide
The number of prescriptions for anti-obesity GLP-1 drugs like Wegovy and Ozempic is rising in North Carolina, just as it is ...
Wellness, GLP-1 weight loss drugs and the Super Bowl—behind the emerging trend
Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.
How GLP-1 medications are transforming diabetes and weight loss treatment
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Neurology Advisor1d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Oprah Winfrey shares experience of taking ‘magic drug’ GLP-1 for weight loss: ‘One of the first things I realised…’
American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...
New York Post13d
Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’
Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...
Modern Healthcare1d
Digital health companies pitch employers on cutting GLP-1 costs
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
Hosted on MSN4h
Looking To Come Off GLP-1 Injectables? Try Calocurb, a Natural Appetite Suppressant, Instead!
Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.